In driver-negative advanced NSCLC, within the subgroups of PD-L1<1% and PD-L1>1%, ICI presented a slightly higher risk of grade 3–5 adverse effects than chemotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.